CompareIsomorphic LabsvsRecursion

Isomorphic Labs is a DeepMind spinout developing AI models for drug discovery, including protein structure prediction and molecule generation for pharmaceutical and biologics partners.

1. Partnership model: Engagement centers on collaborative R&D programs rather than self-serve software subscriptions, making it most relevant to organizations prepared for long-term work.
2. Scientific focus: Its platform applies computational biology and frontier AI to protein and molecule design to accelerate selected discovery workflows.
3. Evidence expectations: The platform does not guarantee clinical outcomes; buyers should examine data access, timelines to validated leads, and each collaboration's cost structure.
4. Buying considerations: Pricing is sales-led and scoped individually, while teams should confirm workflow fit, implementation scope, and available support before committing.

For suitably resourced partners, the central question is whether its collaborative model matches the program's scientific, operational, and commercial requirements.

Recursion is an AI drug discovery company for pharma collaborators and internal programs, combining cellular imaging, automation, and machine learning to identify potential drug candidates.

1. Scientific approach: The platform centers on phenomics and multimodal data, supporting computational biology and R&D acceleration rather than guaranteeing clinical outcomes.
2. Engagement model: Access typically occurs through pharma partnerships instead of self-serve subscriptions, making it relevant to organizations prepared for collaborative discovery.
3. Evaluation priorities: Buyers should examine data-access requirements, timelines to validated leads, validation depth, support coverage, and program-specific costs before committing.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while direct buyer access remains limited to partnerships.

Its fit depends on whether Recursion’s data-rich discovery model, partnership structure, and development timelines align with the buyer’s overall program goals.